 |
| Klarimix Pamphlet |
Warnings:
Clarithromycin is principally excreted via liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in presence of severe renal impairment, with or without coexisting hepatic impairment, dose adjustment is necessary.
Interactions:
Clarithromycin has been shown not to interact with oral contraceptives. As with other macrolide antibiotics, the use of Clarithromycin in patients concurrently taking drugs metabolized by cytochrom P450 s’stem
(e.g warfarin, ergot alkaloids, triazolam, midazolam, disopyramide, lovastatin phenytoin and cyclosporin) may be associated with elevation inserum levels of these other drugs. The administration of Clarithromycin to patients who are receiving theophylline has been associated with an increase in serum ttieophylUne and potentiates theophyfline toxicity.
Clarithromycin is contraindicated in patients receiving terfenadine therapy who have cardiac abnormalities.
Pregnancy and Lactation:
The safety of Clarithromycin during pregnancy and lactation has not been established.
Side Effects:
Clarithromycin is generally well tolerated. Side effects include nausea, dyspepsia, diarrhea, vomiting, abdominal pain, headache, allergic reactions and CNS side effects.
Pseudomembranous colitis has been reported rarely with clarithromycin.
Dosage Regimen:
For adults: 250 mg twice daily for 7 days in mild to moderate infections. 500 mg twice daily for up to 14 days in severe infections.
For children: Older than 12 years: as for adults.
Younger than 12 years: 7.5 mg / Kg body-weight up to 500 mg b.i.d. for 5 to 10 days according to severity of the condition.
Presentation:
Klarimix 250 mg and 500 mg Tablets:
A box containing 2 blisters, each of 7 tablets.
KIarimix 125 mg /5 ml Powder Pro Suspension:
Bottles for preparation of 60 ml.
KIarimix 250 mg /5 ml Powder Pro Suspension:
Bottles for preparation of 60 ml. Produced by SIGMA Pharmaceutical Industries S.A.E. Egypt 0412022
Clarithromycin is principally excreted via liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in presence of severe renal impairment, with or without coexisting hepatic impairment, dose adjustment is necessary.
Interactions:
Clarithromycin has been shown not to interact with oral contraceptives. As with other macrolide antibiotics, the use of Clarithromycin in patients concurrently taking drugs metabolized by cytochrom P450 s’stem
(e.g warfarin, ergot alkaloids, triazolam, midazolam, disopyramide, lovastatin phenytoin and cyclosporin) may be associated with elevation inserum levels of these other drugs. The administration of Clarithromycin to patients who are receiving theophylline has been associated with an increase in serum ttieophylUne and potentiates theophyfline toxicity.
Clarithromycin is contraindicated in patients receiving terfenadine therapy who have cardiac abnormalities.
Pregnancy and Lactation:
The safety of Clarithromycin during pregnancy and lactation has not been established.
Side Effects:
Clarithromycin is generally well tolerated. Side effects include nausea, dyspepsia, diarrhea, vomiting, abdominal pain, headache, allergic reactions and CNS side effects.
Pseudomembranous colitis has been reported rarely with clarithromycin.
Dosage Regimen:
For adults: 250 mg twice daily for 7 days in mild to moderate infections. 500 mg twice daily for up to 14 days in severe infections.
For children: Older than 12 years: as for adults.
Younger than 12 years: 7.5 mg / Kg body-weight up to 500 mg b.i.d. for 5 to 10 days according to severity of the condition.
Presentation:
Klarimix 250 mg and 500 mg Tablets:
A box containing 2 blisters, each of 7 tablets.
KIarimix 125 mg /5 ml Powder Pro Suspension:
Bottles for preparation of 60 ml.
KIarimix 250 mg /5 ml Powder Pro Suspension:
Bottles for preparation of 60 ml. Produced by SIGMA Pharmaceutical Industries S.A.E. Egypt 0412022
Comments
Post a Comment